{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04291859",
            "orgStudyIdInfo": {
                "id": "18252A"
            },
            "secondaryIdInfos": [
                {
                    "id": "2019-001280-77",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "H. Lundbeck A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "Lu AF28996 in Participants With Parkinson's Disease (PD)",
            "officialTitle": "Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "lu-in-participants-with-parkinson-s-disease-pd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-02-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-20",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-20",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-02-28",
            "studyFirstSubmitQcDate": "2020-02-28",
            "studyFirstPostDateStruct": {
                "date": "2020-03-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "H. Lundbeck A/S",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.",
            "detailedDescription": "The study consists of different parts. Part A of the study will consist of once daily (OD) cohorts (OD Cohort 1 to 4\\[5\\]), as well as twice daily (BID) cohorts (BID Cohorts A1 and A2). Part B and Part C have been added to the study. Part B will consist of 2 cohorts (Cohorts B1 and B2) whereby participants will be administered Lu AF28996 BID. Part C will consist of 2 cohorts (Cohorts C1 and C2) whereby participants will be administered three times daily (TID) Lu AF28996."
        },
        "conditionsModule": {
            "conditions": [
                "Parkinson Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 77,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Lu AF28996",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14) in all OD Cohorts 1-4 (5). On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.\n\nFor the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days (Day 1 to Day 24), followed by down-titration as per Investigator's judgement.\n\nFor the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days (Day 1 to Day 39), followed by down-titration as per Investigator's judgement.\n\nFor Part B BID Cohorts B1 and B2, participants will receive Lu AF28996 BID for up to 49 days, followed by down-titration as per Investigator's judgement. For Part C TID Cohorts C1 and C2, participants will receive Lu AF28996 for up to 49 days, followed by down-titration as per Investigator's judgement.",
                    "interventionNames": [
                        "Drug: Lu AF28996"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lu AF28996",
                    "description": "capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences",
                    "armGroupLabels": [
                        "Lu AF28996"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Treatment-emergent Adverse Events",
                    "description": "Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)",
                    "timeFrame": "From Baseline to Day 62"
                },
                {
                    "measure": "AUC(last) of Lu AF28996",
                    "description": "Area under the plasma concentration time curve from zero to last quantifiable plasma concentration",
                    "timeFrame": "0 (predose) to 24 hours postdose on Day 1 to Day 41"
                },
                {
                    "measure": "AUC(0-24h) of Lu AF28996",
                    "description": "Area under the plasma concentration time curve from zero to 24 hours post dose",
                    "timeFrame": "0 (predose) to 24 hours postdose on Day 1 to Day 41"
                },
                {
                    "measure": "Cmax of Lu AF28996",
                    "description": "Maximum observed plasma concentration of Lu AF28996",
                    "timeFrame": "0 (predose) to 24 hours postdose on Day 1 to Day 41"
                },
                {
                    "measure": "CL/F of Lu AF28996",
                    "description": "Oral clearance for Lu AF28996 in plasma",
                    "timeFrame": "0 (predose) to 24 hours postdose on Day 1 to Day 41"
                },
                {
                    "measure": "Amount of Lu AF28996, Lu AF28995, Lu AF29308, and Lu AF29309 Excreted in Urine",
                    "timeFrame": "0 (predose) to 24 hours postdose on Day 1 to Day 62"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nPart A\n\n* Participants diagnosed with idiopathic PD (consistent with the UK PD Society Brain Bank Criteria for the Diagnosis of PD), with not more than 1 first-degree relative who has PD.\n* Participants must have a Modified Hoehn and Yahr score \u22644 in the OFF state and \u22643 in the ON state, and a Mini Mental State Examination score \\>25.\n* The OFF/ON amplitude on the MDS-UPDRS Part III at screening must be minimum 30% difference.\n* Participants must experience recognizable and predictable motor fluctuations (with at least 1.5 hours of OFF periods in the awake time, including predictable morning OFF episodes), causing clinically significant disability during the 7-week Screening Period, as evaluated by the investigator. This will be documented using a participant ON/OFF state registration over 3 consecutive days prior to enrolment.\n* Allowed concomitant medication for PD during the study includes levodopa, monoamine oxidase B inhibitors, COMT inhibitors, anticholinergics, and amantadine. Dopamine agonists are not allowed and should be discontinued \u22654 weeks prior to dosing with Lu AF28996 and until the end of the study.\n\nPart B and Part C\n\n* Participants diagnosed with idiopathic PD (consistent with the UK PD Society Brain Bank Criteria for the Diagnosis of PD), with not more than 1 first-degree relative who has PD.\n* Participants must have a Modified Hoehn and Yahr score \u22652 to \u22644 in the OFF state and \u22643 in the ON state, a MDS-UPDRS Part IV, 4.5 score of 1 or 2, and a MDS-UPDRS Part IV, 4.2 score \u22652 (at least mild functional impact), and a Mini Mental State Examination score \\>25 at the Screening Visit.\n* Participants must currently have a good response to levodopa and be receiving a stable dose of levodopa (\u22653 doses per day of levodopa/dopa decarboxylase inhibitor therapy or \u22653 doses per day of levodopa Extended-Release Capsules and LEDD between 400 and 1600, inclusive) for at least 4 weeks prior to screening.\n* Participants must experience recognizable and predictable motor fluctuations (with \u22653 hours of OFF periods in the awake time, including predictable morning OFF episodes), causing clinically significant disability during 3 months prior to enrolment, as evaluated by the investigator. The criteria will be documented using Hauser Diary over 3 consecutive days prior to enrolment.\n* Participants must experience \u22651 hour daily ON time with troublesome dyskinesia (TD) in the awake time (TD/24 hours while awake) during the last 3 months prior to enrolment as evaluated by the investigator. The criteria will be documented using the Hauser Diary over 3 consecutive days prior to enrolment.\n* Allowed concomitant medication for PD during the study includes levodopa, dopamine agonists, if allowed daily dose, monoamine oxidase B inhibitors, COMT inhibitors, anticholinergics, and amantadine.\n\nExclusion Criteria:\n\n* The participant has or had one or more of the following conditions that are considered clinically relevant in the context of the study; other neurological disorder, psychiatric disorder, seizure disorder or encephalopathy, respiratory disease, hepatic impairment or renal insufficiency, metabolic disorder, endocrinological disorder, haematological disorder, infectious disorder, any clinically significant immunological condition, or a history of narrow-angle glaucoma.\n* Participant has been treated with apomorphine (pen/pump), or levodopa/carbidopa intestinal gel (LCIG), within 6 weeks prior to the Baseline Visit.\n* Participants formerly treated with oral or transdermal dopamine agonists must have discontinued 4 weeks prior to screening.\n* Participant has a history of Dopamine Agonist Withdrawal Syndrome (DAWS) when dopamine agonists were previously discontinued or reduced.\n\nOther inclusion and exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "45 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Email contact via H. Lundbeck A/S",
                    "role": "CONTACT",
                    "phone": "+45 36301311",
                    "email": "LundbeckClinicalTrials@Lundbeck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Email contact via H. Lundbeck A/S",
                    "affiliation": "LundbeckClinicalTrials@Lundbeck.com",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Velocity",
                    "status": "RECRUITING",
                    "city": "Hallandale Beach",
                    "state": "Florida",
                    "zip": "33009",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.9812,
                        "lon": -80.14838
                    }
                },
                {
                    "facility": "Atlanta Center for Medical Research",
                    "status": "COMPLETED",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "QUEST Research Institute",
                    "status": "RECRUITING",
                    "city": "Farmington Hills",
                    "state": "Michigan",
                    "zip": "48334",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.48531,
                        "lon": -83.37716
                    }
                },
                {
                    "facility": "QPS Netherlands BV",
                    "status": "COMPLETED",
                    "city": "Leeuwarden",
                    "zip": "8934 AD",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 53.20139,
                        "lon": 5.80859
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010300",
                    "term": "Parkinson Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020734",
                    "term": "Parkinsonian Disorders"
                },
                {
                    "id": "D000001480",
                    "term": "Basal Ganglia Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000080874",
                    "term": "Synucleinopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13213",
                    "name": "Parkinson Disease",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22494",
                    "name": "Parkinsonian Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M25603",
                    "name": "Ganglion Cysts",
                    "relevance": "LOW"
                },
                {
                    "id": "M16358",
                    "name": "Synovial Cyst",
                    "relevance": "LOW"
                },
                {
                    "id": "M4774",
                    "name": "Basal Ganglia Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2217",
                    "name": "Synucleinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        }
    },
    "hasResults": false
}